Literature DB >> 23278516

Angiotensin I-converting enzyme gene (I/D) polymorphism in patients with migraine.

Bahriye Horasanlı1, F Belgin Ataç2, İlker Çöven3, Basak Karakurum Goksel1, Sibel Benli1.   

Abstract

In addition to the wide expression in many tissues including vascular endothelial cells, production of angiotensin II and degradation of bradykinin may indicate that angiotensin-converting enzyme could be involved in vascular tension and blood pressure. It has been reported that the deletion allele of the angiotensin-converting enzyme gene is associated with increased serum angiotensin-converting enzyme levels and linked to cerebrovascular diseases. In this study, the possible association of migraine with aura with the angiotensin-converting enzyme deletion-deletion (DD) and the angiotensin-converting enzyme insertion-deletion (ID) genotype was investigated in Turkish patients. To investigate the role of the angiotensin-converting enzyme I/D polymorphism in Turkish patients with migraine with aura, we analyzed the I/D genotype of 53 patients with that disorder. Twenty-two control subjects, who are volunteer Turkish patients without migraine, were included in the study. The frequency of the angiotensin-converting enzyme D/D genotype was statistically significant more frequent in patients with migraine with aura (81.1%) than in controls (59.1%) (P < .05). No differences were found regarding the I/I genotype and the I/D genotype between the 2 groups (P > .05). The results of our study revealed that the angiotensin-converting enzyme D/D genotype was more frequent in patients with migraine with aura than in controls. This might suggest that the angiotensin-converting enzyme D/D genotype may be a genetic risk factor for migraine with aura in Turkish patients.
© 2012 American Headache Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23278516     DOI: 10.1111/head.12008

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  5 in total

1.  ACE and ARB Agents in the Prophylactic Therapy of Migraine-How Effective Are They?

Authors:  Rashmi B Halker; Amaal J Starling; Bert B Vargas; Todd J Schwedt
Journal:  Curr Treat Options Neurol       Date:  2016-04       Impact factor: 3.598

Review 2.  Role of angiotensin modulation in primary headaches.

Authors:  Erling Tronvik; Lars Jacob Stovner
Journal:  Curr Pain Headache Rep       Date:  2014-05

3.  Treatment with telmisartan, a long-acting angiotensin II receptor blocker, prevents migraine attacks in Japanese non-responders to lomerizine.

Authors:  Ken Ikeda; Sayori Hanashiro; Yuichi Ishikawa; Masahiro Sawada; Maya Kyuzen; Harumi Morioka; Junya Ebina; Junpei Nagasawa; Masaru Yanagihashi; Ken Miura; Takehisa Hirayama; Takanori Takazawa; Osamu Kano; Kiyokazu Kawabe; Yasuo Iwasaki
Journal:  Neurol Sci       Date:  2017-02-21       Impact factor: 3.307

4.  Hypertension and Migraine in the Northern Manhattan Study.

Authors:  Hannah Gardener; Teshamae Monteith; Tatjana Rundek; Clinton B Wright; Mitchell S V Elkind; Ralph L Sacco
Journal:  Ethn Dis       Date:  2016-07-21       Impact factor: 1.847

5.  Association of ACE Gene I/D polymorphism with migraine in Kashmiri population.

Authors:  Irfan Yousuf Wani; Saleem Sheikh; Zafar Amin Shah; Arshid A Pandith; Mushtaq Wani; Ravouf Asimi; Maqbool Wani; Shahnawaz Sheikh; Iqra Mehraj
Journal:  Ann Indian Acad Neurol       Date:  2016 Jan-Mar       Impact factor: 1.383

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.